Clinical Trial

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-06-04; most recent amendment 2026-04-21.
Status change: Not Yet Recruiting → Recruiting 2025-06-13
Trial Details
NCT Number NCT07020221
Lead Sponsor Verastem, Inc.
Conditions Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Enrollment 295 participants
Start Date 2025-06-24
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-22